420 related articles for article (PubMed ID: 26121086)
1. Mutational dynamics between primary and relapse neuroblastomas.
Schramm A; Köster J; Assenov Y; Althoff K; Peifer M; Mahlow E; Odersky A; Beisser D; Ernst C; Henssen AG; Stephan H; Schröder C; Heukamp L; Engesser A; Kahlert Y; Theissen J; Hero B; Roels F; Altmüller J; Nürnberg P; Astrahantseff K; Gloeckner C; De Preter K; Plass C; Lee S; Lode HN; Henrich KO; Gartlgruber M; Speleman F; Schmezer P; Westermann F; Rahmann S; Fischer M; Eggert A; Schulte JH
Nat Genet; 2015 Aug; 47(8):872-7. PubMed ID: 26121086
[TBL] [Abstract][Full Text] [Related]
2. Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis.
Carlsson E; Krohn K; Ovaska K; Lindberg P; Häyry V; Maliniemi P; Lintulahti A; Korja M; Kivisaari R; Hussein S; Sarna S; Niiranen K; Hautaniemi S; Haapasalo H; Ranki A
Genes Chromosomes Cancer; 2013 Feb; 52(2):191-201. PubMed ID: 23097141
[TBL] [Abstract][Full Text] [Related]
3. Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma.
Chicard M; Colmet-Daage L; Clement N; Danzon A; Bohec M; Bernard V; Baulande S; Bellini A; Deveau P; Pierron G; Lapouble E; Janoueix-Lerosey I; Peuchmaur M; Corradini N; Defachelles AS; Valteau-Couanet D; Michon J; Combaret V; Delattre O; Schleiermacher G
Clin Cancer Res; 2018 Feb; 24(4):939-949. PubMed ID: 29191970
[No Abstract] [Full Text] [Related]
4. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
5. Estimation of copy number aberrations: Comparison of exome sequencing data with SNP microarrays identifies homozygous deletions of 19q13.2 and CIC in neuroblastoma.
Fransson S; Östensson M; Djos A; Javanmardi N; Kogner P; Martinsson T
Int J Oncol; 2016 Mar; 48(3):1103-16. PubMed ID: 26794043
[TBL] [Abstract][Full Text] [Related]
6. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
7. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Eleveld TF; Oldridge DA; Bernard V; Koster J; Colmet Daage L; Diskin SJ; Schild L; Bentahar NB; Bellini A; Chicard M; Lapouble E; Combaret V; Legoix-Né P; Michon J; Pugh TJ; Hart LS; Rader J; Attiyeh EF; Wei JS; Zhang S; Naranjo A; Gastier-Foster JM; Hogarty MD; Asgharzadeh S; Smith MA; Guidry Auvil JM; Watkins TB; Zwijnenburg DA; Ebus ME; van Sluis P; Hakkert A; van Wezel E; van der Schoot CE; Westerhout EM; Schulte JH; Tytgat GA; Dolman ME; Janoueix-Lerosey I; Gerhard DS; Caron HN; Delattre O; Khan J; Versteeg R; Schleiermacher G; Molenaar JJ; Maris JM
Nat Genet; 2015 Aug; 47(8):864-71. PubMed ID: 26121087
[TBL] [Abstract][Full Text] [Related]
8. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
[TBL] [Abstract][Full Text] [Related]
9. Stathmin levels alter PTPN14 expression and impact neuroblastoma cell migration.
Po'uha ST; Le Grand M; Brandl MB; Gifford AJ; Goodall GJ; Khew-Goodall Y; Kavallaris M
Br J Cancer; 2020 Feb; 122(3):434-444. PubMed ID: 31806880
[TBL] [Abstract][Full Text] [Related]
10. Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.
Lasorsa VA; Formicola D; Pignataro P; Cimmino F; Calabrese FM; Mora J; Esposito MR; Pantile M; Zanon C; De Mariano M; Longo L; Hogarty MD; de Torres C; Tonini GP; Iolascon A; Capasso M
Oncotarget; 2016 Apr; 7(16):21840-52. PubMed ID: 27009842
[TBL] [Abstract][Full Text] [Related]
11. Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas.
Naraparaju K; Kolla V; Zhuang T; Higashi M; Iyer R; Kolla S; Okawa ER; Blobel GA; Brodeur GM
Oncotarget; 2016 Mar; 7(13):15977-85. PubMed ID: 26895110
[TBL] [Abstract][Full Text] [Related]
12. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.
Molenaar JJ; Koster J; Zwijnenburg DA; van Sluis P; Valentijn LJ; van der Ploeg I; Hamdi M; van Nes J; Westerman BA; van Arkel J; Ebus ME; Haneveld F; Lakeman A; Schild L; Molenaar P; Stroeken P; van Noesel MM; Ora I; Santo EE; Caron HN; Westerhout EM; Versteeg R
Nature; 2012 Feb; 483(7391):589-93. PubMed ID: 22367537
[TBL] [Abstract][Full Text] [Related]
13. Loss of ALK hotspot mutations in relapsed neuroblastoma.
Allinson LM; Potts A; Goodman A; Bown N; Bashton M; Thompson D; Basta NO; Gabriel AS; McCorkindale M; Ng A; McNally RJQ; Tweddle DA
Genes Chromosomes Cancer; 2022 Dec; 61(12):747-753. PubMed ID: 36029175
[TBL] [Abstract][Full Text] [Related]
14. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
Fransson S; Martinez-Monleon A; Johansson M; Sjöberg RM; Björklund C; Ljungman G; Ek T; Kogner P; Martinsson T
Sci Rep; 2020 Dec; 10(1):22432. PubMed ID: 33384420
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of copy number and gene expression data identifies potential oncogenic drivers that promote mammary tumor recurrence.
Jones RA; Moorehead RA
Genes Chromosomes Cancer; 2019 Jun; 58(6):381-391. PubMed ID: 30597648
[TBL] [Abstract][Full Text] [Related]
16. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
17. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.
Gorringe KL; Choong DY; Williams LH; Ramakrishna M; Sridhar A; Qiu W; Bearfoot JL; Campbell IG
Neoplasia; 2008 Nov; 10(11):1253-8. PubMed ID: 18953434
[TBL] [Abstract][Full Text] [Related]
18. Emergence of new ALK mutations at relapse of neuroblastoma.
Schleiermacher G; Javanmardi N; Bernard V; Leroy Q; Cappo J; Rio Frio T; Pierron G; Lapouble E; Combaret V; Speleman F; de Wilde B; Djos A; Ora I; Hedborg F; Träger C; Holmqvist BM; Abrahamsson J; Peuchmaur M; Michon J; Janoueix-Lerosey I; Kogner P; Delattre O; Martinsson T
J Clin Oncol; 2014 Sep; 32(25):2727-34. PubMed ID: 25071110
[TBL] [Abstract][Full Text] [Related]
19. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics.
Modena P; Lualdi E; Facchinetti F; Veltman J; Reid JF; Minardi S; Janssen I; Giangaspero F; Forni M; Finocchiaro G; Genitori L; Giordano F; Riccardi R; Schoenmakers EF; Massimino M; Sozzi G
J Clin Oncol; 2006 Nov; 24(33):5223-33. PubMed ID: 17114655
[TBL] [Abstract][Full Text] [Related]
20. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer.
Pan Y; Tong JHM; Lung RWM; Kang W; Kwan JSH; Chak WP; Tin KY; Chung LY; Wu F; Ng SSM; Mak TWC; Yu J; Lo KW; Chan AWH; To KF
Mol Cancer; 2018 Jul; 17(1):102. PubMed ID: 30037330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
